MeiraGTx is developing AAV-AQP1 to treat radiation-induced xerostomia (RIX) by increasing water conduction in the salivary glands damaged by radiation therapy. Our gene therapy product candidate works by introducing a water conducting channel into the remaining epithelial cells of these damaged glands.

We are currently conducting a Phase 1 clinical trial in patients who have survived cancer free for five or more years following treatment for head and neck cancer and are suffering from grade 2 or 3 RIX. We have also initiated the AQUAx trial,  a multi-site Phase 1 clinical trial enrolling participants who have been diagnosed with grade 2 or 3 RIX and who have remained cancer free for at least five years (or two years if HPV+) after receiving radiation treatment for head and neck cancer.